S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: The truth about war with China (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
The World's First "$20 Trillion Drug (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
The World's First "$20 Trillion Drug (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: The truth about war with China (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
The World's First "$20 Trillion Drug (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
The World's First "$20 Trillion Drug (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: The truth about war with China (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
The World's First "$20 Trillion Drug (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
The World's First "$20 Trillion Drug (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: The truth about war with China (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
The World's First "$20 Trillion Drug (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
The World's First "$20 Trillion Drug (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
NASDAQ:INCR

InterCure (INCR) Stock Forecast, Price & News

$1.65
-0.02 (-1.20%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.65
$1.70
50-Day Range
$1.39
$1.72
52-Week Range
$1.39
$5.56
Volume
25,619 shs
Average Volume
44,491 shs
Market Capitalization
N/A
P/E Ratio
12.69
Dividend Yield
N/A
Price Target
$5.00

InterCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
203.0% Upside
$5.00 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars


INCR stock logo

About InterCure (NASDAQ:INCR) Stock

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

INCR Price History

INCR Stock News Headlines

Closing Bell: Intercure Ltd up on Monday (INCR-U)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Closing Bell: Intercure Ltd down on Monday (INCR-U)
Closing Bell: Intercure Ltd flat on Monday (INCR-U)
Closing Bell: Intercure Ltd flat on Friday (INCR-U)
Closing Bell: Intercure Ltd down on Friday (INCR-U)
Closing Bell: Intercure Ltd flat on Wednesday (INCR-U)
Closing Bell: Intercure Ltd down on Wednesday (INCR-U)
Closing Bell: Intercure Ltd up on Thursday (INCR-U)
Intercure Ltd
See More Headlines
Receive INCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter.

INCR Company Calendar

Today
9/20/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INCR
Fax
N/A
Employees
370
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+203.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$13.36 million
Pretax Margin
6.32%

Debt

Sales & Book Value

Annual Sales
$115.83 million
Cash Flow
$0.38 per share
Book Value
$3.64 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.03
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Alexander Rabinovitch (Age 52)
    CEO & Director
  • Mr. Amos Cohen (Age 44)
    Chief Financial Officer
  • Einat Zehavi
    VP of Sales
  • Mr. Rami Levy (Age 58)
    Chief Operating Officer of Canndoc
  • Mr. Omri Batzir
    Corp. Controller













INCR Stock - Frequently Asked Questions

Should I buy or sell InterCure stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InterCure in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INCR shares.
View INCR analyst ratings
or view top-rated stocks.

What is InterCure's stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month price targets for InterCure's stock. Their INCR share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for INCR
or view top-rated stocks among Wall Street analysts.

How have INCR shares performed in 2023?

InterCure's stock was trading at $3.30 at the beginning of the year. Since then, INCR stock has decreased by 50.0% and is now trading at $1.65.
View the best growth stocks for 2023 here
.

Are investors shorting InterCure?

InterCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,900 shares, an increase of 156.6% from the August 15th total of 13,600 shares. Based on an average daily volume of 46,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's shares are short sold.
View InterCure's Short Interest
.

When is InterCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our INCR earnings forecast
.

What is InterCure's stock symbol?

InterCure trades on the NASDAQ under the ticker symbol "INCR."

Who are InterCure's major shareholders?

InterCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.20%), Cambria Investment Management L.P. (0.14%) and Citadel Advisors LLC (0.00%).

How do I buy shares of InterCure?

Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InterCure's stock price today?

One share of INCR stock can currently be purchased for approximately $1.65.

How many employees does InterCure have?

The company employs 370 workers across the globe.

How can I contact InterCure?

The official website for the company is www.intercure.co. The company can be reached via phone at 972774605012.

This page (NASDAQ:INCR) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -